4.3 USD
-0.06 (-1.38%)
4.2745 USD
-0.03 (-0.59%)
We assign a fundamental rating of 5 out of 10 to ORGO. ORGO was compared to 530 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
ORGO had a negative operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
In the past 5 years ORGO always reported a positive cash flow from operatings.
1.2 Ratios
ORGO has a Return On Assets of -2.63%. This is amongst the best in the industry. ORGO outperforms 87.55% of its industry peers.
ORGO has a Return On Equity of -3.47%. This is amongst the best in the industry. ORGO outperforms 89.25% of its industry peers.
ORGO's Return On Invested Capital of 0.16% is amongst the best of the industry. ORGO outperforms 88.87% of its industry peers.
ORGO had an Average Return On Invested Capital over the past 3 years of 3.79%. This is significantly below the industry average of 18.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROIC | 0.16% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
The Operating Margin of ORGO (0.18%) is better than 88.87% of its industry peers.
In the last couple of years the Operating Margin of ORGO has declined.
ORGO has a better Gross Margin (74.49%) than 83.40% of its industry peers.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ORGO has less shares outstanding
The number of shares outstanding for ORGO has been increased compared to 5 years ago.
The debt/assets ratio for ORGO has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.96 indicates that ORGO is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.96, ORGO is doing good in the industry, outperforming 71.32% of the companies in the same industry.
ORGO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ORGO has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ORGO outperforms 46.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.96 |
ROIC/WACC0.02
WACC8.96%
2.3 Liquidity
ORGO has a Current Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.32, ORGO is doing worse than 60.19% of the companies in the same industry.
ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO's Quick ratio of 2.88 is on the low side compared to the rest of the industry. ORGO is outperformed by 63.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
The earnings per share for ORGO have decreased strongly by -90.91% in the last year.
The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad
Looking at the last year, ORGO shows a small growth in Revenue. The Revenue has grown by 2.24% in the last year.
The Revenue has been growing by 13.05% on average over the past years. This is quite good.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
3.2 Future
Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 29.27% on average per year.
ORGO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.70% yearly.
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 430.00, ORGO can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 88.87% of the companies listed in the same industry.
ORGO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.92.
Based on the Price/Forward Earnings ratio of 29.07, the valuation of ORGO can be described as expensive.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 92.26% of the companies are valued more expensively.
ORGO is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 430 | ||
| Fwd PE | 29.07 |
4.2 Price Multiples
ORGO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ORGO is cheaper than 93.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 25.89 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 29.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
5. Dividend
5.1 Amount
ORGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
4.3
-0.06 (-1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners54.62%
Inst Owner Change0%
Ins Owners31.34%
Ins Owner Change-0.43%
Market Cap545.71M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.67 (101.63%)
Short Float %16.7%
Short Ratio5.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)6.25%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.48%
EPS NY rev (1m)0%
EPS NY rev (3m)216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 430 | ||
| Fwd PE | 29.07 | ||
| P/S | 1.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.41 | ||
| P/tB | 1.57 | ||
| EV/EBITDA | 25.89 |
EPS(TTM)0.01
EY0.23%
EPS(NY)0.15
Fwd EY3.44%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROCE | 0.2% | ||
| ROIC | 0.16% | ||
| ROICexc | 0.19% | ||
| ROICexgc | 0.21% | ||
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 70.73% | ||
| Cap/Sales | 2.76% | ||
| Interest Coverage | 0.99 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z | 3.96 |
F-Score2
WACC8.96%
ROIC/WACC0.02
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year563.55%
EBIT Next 3Y112.83%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 5 / 10 to ORGO.
Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
What is the profitability of ORGO stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.
What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?
The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.